Back to search

Article

Targeted inhibition of SCF <sup>SKP2</sup> confers anti-tumor activities resulting in a survival benefit in osteosarcoma

2023-05-14

Abstract excerpt

Osteosarcoma(OS) is a highly aggressive bone cancer for which treatment has remained essentially unchanged for decades. Although OS is characterized by extensive genomic heterogeneity and instability, RB1 and TP53 have been shown to be the most commonly inactivated tumor suppressors in OS. We previously generated a mouse model with a double knockout (DKO) of Rb1 and Trp53 within cells of the osteoblastic linea...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work
ad7aeff9-2933-52a8-b28c-78976c84bc0a
DOI
10.1101/2023.05.13.540637
Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest
Interactive article relationship graphSelect a related publication card to move it into the centre and load its closest explainable connections. Solid lines are source-backed structured connections. Dashed lines are semantic discovery signals and are not scientific evidence.
Targeted inhibition of SCF <sup>SKP2</sup> confers anti-tumor activities resulting in a survival benefit in osteosarcomaDOI 10.1101/2023.05.13.540637
Select a neighboring publication to make it the new centre.